GlassScriptPhysician profile
Nicholas Koroneos
NPI 1134622913
$4,375.76
in general payments reported to CMS, 2019-2025
35 companies · $2,161 in 2025
The $2,161 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $378 · 2024: $1,837 · 2025: $2,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,219 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,218.82 |
| Education | $156.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.39 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $385.16 | 2023-2025 | |
| Ucb, INC. | $351.82 | 2023-2025 | Rystiggo, Nayzilam, Briviact |
| Teva Pharmaceuticals USA, INC. | $313.21 | 2023-2025 | Austedo Xr, Austedo Xr |
| Acadia Pharmaceuticals INC | $281.88 | 2023-2025 | Nuplazid |
| Lundbeck LLC | $223.26 | 2024-2025 | Vyepti, Rexulti |
| Tg Therapeutics, INC. | $212.60 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $186.93 | 2024-2025 | Crexont, Rytary |
| Alexion Pharmaceuticals, INC. | $166.88 | 2024-2025 | Ultomiris |
| Sk Life Science, INC. | $161.51 | 2023-2025 | |
| Lilly USA, LLC | $161.01 | 2024-2025 | Kisunla, Amyvid |
| Averitas Pharma INC. | $133.51 | 2024-2025 | Qutenza |
| Novus Surgical Consultants | $133.07 | 2024 | |
| Neurocrine Biosciences, INC. | $130.15 | 2023-2025 | Ingrezza |
| Celgene Corporation | $128.82 | 2023-2025 | Zeposia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $101.88 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $98.57 | 2024-2025 | Rexulti, Nuedexta |
| Alnylam Pharmaceuticals INC. | $83.00 | 2023-2025 | Onpattro, Amvuttra |
| Tanabe Pharma America, INC. | $73.30 | 2024 | |
| Biogen, INC. | $71.42 | 2025 | Leqembi |
| Argenx US, INC. | $66.24 | 2024 | Vyvgart Hytrulo |
| Amgen INC. | $62.01 | 2024-2025 | Uplizna |
| Axsome Therapeutics, INC. | $44.24 | 2025 | Symbravo |
| Acorda Therapeutics, INC | $41.34 | 2023-2024 | Inbrija |
| Genzyme Corporation | $40.10 | 2025 | |
| Csl Behring | $33.75 | 2025 | Hizentra |
| Tonix Medicines, INC. | $30.18 | 2025 | Zembrace Symtouch |
| Emd Serono, INC. | $29.08 | 2024 | |
| Horizon Therapeutics Plc | $28.22 | 2023 | Uplizna |
| Merz Pharmaceuticals, LLC | $27.73 | 2025 | Inbrija, Xeomin |
| Kyowa Kirin, INC. | $26.86 | 2024 | Nourianz |
| Mallinckrodt Hospital Products INC. | $23.31 | 2023 | Acthar |
| Eisai INC. | $23.20 | 2024 | |
| Jazz Pharmaceuticals INC. | $21.63 | 2025 | |
| Grifols USA, LLC | $20.50 | 2024 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Koroneos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.